T he four parathyroid glands, located posterior to the thyroid gland, regulate calcium homeostasis through release of parathyroid hormone (PTH). Because most parathyroid disorders present with abnormalities of serum calcium, they commonly appear in differential diagnoses. Therefore, understanding the presentation and principles of evaluation of parathyroid disorders is important in primary care.
Patients with primary hyperparathyroidism who do not undergo parathyroidectomy should have serum calcium and creatinine levels measured annually, and three-site (i.e., hip, spine, and forearm) bone density measurement every one to two years.
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Family members of a patient with multiple endocrine neoplasia type 2 should be tested for the patient's specific genetic mutation. 
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Volume 88, Number 4 ◆ August 15, 2013 increased mass of the glands. Calcium and 1,25-dihydroxyvitamin D provide negative feedback at the parathyroid glands to inhibit PTH release. One normal gland is sufficient for adequate secretion of PTH to maintain normal calcium levels. 1, 3, 4 Parathyroid disorders most commonly present with serum calcium abnormalities. Rarely, patients can present with a neck mass or for evaluation of a family history of parathyroid or related disorders. The estimated incidence of primary hyperparathyroidism is approximately 25 cases per 100,000 persons per year in outpatients of Western countries, [5] [6] [7] with a prevalence of one to four per 1,000 persons. 8 Hypoparathyroidism most commonly occurs after inadvertent damage or removal of parathyroid glands during neck surgery; estimates for the occurrence of this surgical complication range from 0.5% to 6.6%, with higher rates after repeat neck surgery. 1, 9 Multiple endocrine neoplasia type 1 (MEN-1) and type 2 (MEN-2), which often include parathyroid neoplasia, each occur in about two per 100,000 persons per year. 10 Parathyroid cancer is rare, with an incidence of approximately four per 10 million persons per year.
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Hyperparathyroidism
PRIMARY
Primary hyperparathyroidism, the most common cause of hypercalcemia in outpatients, is often discovered incidentally during evaluation of serum electrolyte levels. Before the easily available measurement of serum calcium levels, patients presented with a spectrum of symptoms (Table 1) . 4, 12, 13 Most patients today are asymptomatic, with nephrolithiasis occurring in up to 15% of patients, bone disease (formerly osteitis fibrosa cystica) occurring in 2% of patients, and neuromuscular symptoms occurring rarely. 3, 14, 15 Although marked symptoms are uncommon in Western countries, it is important to be aware that subtle and nonspecific symptoms may be present. [14] [15] [16] Other causes of hypercalcemia are listed in Table 2 . 3, 5, 8, 17, 18 Overall, 85% of patients with primary hyperparathyroidism have a single adenoma. Risk factors for primary hyperparathyroidism include a history of neck radiation, age Figure 1 . Control of mineral metabolism by parathyroid hormone (PTH). Calcium-sensing receptors of parathyroid cells respond to serum calcium level and change with increased release (hypocalcemia) or suppression (hypercalcemia) of PTH. PTH stimulates bone resorption, which increases serum calcium and phosphorus. In the kidney, PTH stimulates reabsorption of calcium and promotes phosphorus excretion. PTH also helps convert 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D in the kidneys, which then increases intestinal transport of calcium and phosphorus. 
SECONDARY
Secondary hyperparathyroidism most commonly occurs because of decreased levels of 1,25-dihydroxyvitamin D, hyperphosphatemia, and hypocalcemia in the setting of chronic kidney disease. Other causes include vitamin D deficiency secondary to low dietary intake, lack of sun exposure, malabsorption, liver disease, and other chronic illness. 20 In some patients with advanced renal failure, hypercalcemia is due to progression from appropriate parathyroid hyperplasia to autonomous overproduction of PTH, a disorder termed tertiary hyperparathyroidism. 12, 20 Patients with normocalcemic hyperparathyroidism may present with low bone density, osteoporosis, or a fragility fracture. Many of these patients will probably evolve into having hyperparathyroidism, although the exact natural history is not known. It is important to exclude vitamin D deficiency and chronic kidney disease before making this diagnosis.
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EVALUATION
Primary hyperparathyroidism is diagnosed when the serum calcium level is elevated, with an increased or inappropriately normal serum PTH level. An algorithm for the evaluation of patients with suggestive symptoms or asymptomatic hypercalcemia is shown in Figure 2 . 2, 4, 8, 10, [21] [22] [23] Hypercalcemia should be verified, and vitamin D levels should be measured and determined to be adequate before parathyroid disorder is considered. 18 In patients with hypercalcemia, the PTH level distinguishes PTH-mediated from non-PTH-mediated hypercalcemia. A physical examination is important to identify subtle features consistent with hyperparathyroidism and to assist in the differential diagnosis (Table 3) . 1, 4, 8, 24 Other tests listed in Figure 2 should identify patients with primary hyperparathyroidism. 2, 4, 8, 10, [21] [22] [23] Familial hypocalciuric hypercalcemia results from an inactivating mutation of the calcium-sensing receptor gene, and patients with this disorder require a higher level of calcium to suppress PTH secretion; they may present with high calcium levels, normal or elevated PTH levels, and low urinary calcium secretion. 8 Referral to an endocrinologist (or other specialist if an etiology for hypercalcemia other than primary hyperparathyroidism is found) is often indicated after this stepwise evaluation.
INDICATIONS FOR SURGERY
Patients with primary hyperparathyroidism and symptoms or signs should undergo surgical removal of their parathyroid gland(s). 25, 26 In some patients, medical comorbidities may preclude surgery, and controlling hypercalcemia alone may be the goal. In this situation, the calcimimetic cinacalcet (Sensipar) effectively lowers serum calcium levels, but does not affect bone density.
27,28 Age alone should not preclude parathyroidectomy. 29 The role of surgery in patients with asymptomatic primary hyperparathyroidism is not as clear. Younger patients and patients at risk of progression to symptomatic disease are the best candidates for parathyroidectomy. Recommendations from the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism include performing parathyroidectomy in asymptomatic persons with primary hyperparathyroidism and any one of the following 26 :
• Serum calcium level greater than 1. • Bone mineral density T-score of less than -2.5 at any one of three sites (i.e., hip, spine, or wrist) and/or any previous fragility fracture (z scores should be used in premenopausal women and in men younger than 50 years)
• Age younger than 50 years
In one study, 15% of asymptomatic patients developed an indication for surgery over an average of 4.7 years. 6 Asymptomatic persons with primary hyperparathyroidism and osteoporosis or osteopenia are candidates for parathyroidectomy because bone density and fracture risk improve after surgery. Bone density, but not fracture risk, has also been shown to improve after bisphosphonate therapy and hormone therapy in these patients. 27 The relationship between neurocognitive function and primary hyperparathyroidism is somewhat controversial, but some studies show improvement in neurocognitive function after parathyroidectomy. 16, 27, 30, 31 Other reviews conclude that surgery and medical management improve bone density; however, there were no differences in quality of life. 32, 33 If patients with primary hyperparathyroidism do not undergo parathyroidectomy, they should be closely monitored for the development of symptoms or other indications for surgery. These patients should have serum calcium and creatinine levels measured annually, and three-site (i.e., hip, spine, and forearm) bone density measurement every one to two years (PTH has a catabolic effect on cortical bone, and this change may only be evident in the distal forearm). 15, 26 The management of secondary hyperparathyroidism in chronic kidney disease usually involves consultation with a nephrologist. Protein restriction and calcium supplementation have been shown to decrease the development of this complication, with a reduction in death from renal causes. Vitamin D supplements and calcimimetics, which inhibit PTH secretion, have been shown to improve biochemical markers (without patient-oriented outcomes). There are several evidence-based reviews for managing chronic kidney disease-mineral and bone disorder; full discussion of these guidelines is beyond the scope of this article and is available from this referenced source. 34 
Hypoparathyroidism
Hypoparathyroidism most commonly occurs after inadvertent damage or removal of parathyroid glands during neck surgery. It can occur years after neck surgery.
1 Most head and neck surgeons carefully track this complication with intra-and postoperative monitoring of calcium and PTH levels. 31 Autoimmune parathyroid destruction, either isolated or as part of a multiple endocrine deficiency syndrome, is another important cause of hypoparathyroidism. Rarely, there is tissue resistance to the actions of PTH, which results in a picture of hypoparathyroidism but with elevated PTH levels. This is termed pseudohypoparathyroidism, and it is a genetically heterogeneous condition. 1, 24 These and other causes of hypoparathyroidism are listed in Table 4 . 1, 3, 24 Most patients with hypoparathyroidism present with hypocalcemia. Figure 3 is an algorithm for evaluating patients with symptomatic or incidentally discovered hypocalcemia. [1] [2] [3] [4] 24 In some patients, such as those with acute pancreatitis, sepsis, or other critical illness, the cause of hypocalcemia is apparent, and treatment without full evaluation is warranted. Table 5 lists causes of hypocalcemia based on clinical clues. 1, 24 Symptoms associated with hypocalcemia depend on the severity, duration, and rate of development; common symptoms are listed in Table 6 . 1, 3, 24 Physical findings are listed in Table 3 . 1, 4, 8, 24 It is important to ensure repletion to normal levels of vitamin D and magnesium in these patients. Serum levels of PTH, phosphorus, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D can help differentiate between disorders causing hypocalcemia (Table 7) . 22 Figure 3 provides brief recommendations for the immediate treatment of severe hypocalcemia [1] [2] [3] [4] 24 ; a detailed discussion is beyond the scope of this article. Long-term management of hypoparathyroidism should include at least initial involvement of an endocrinologist. Vitamin D analogues are essential (e.g., calcitriol [Rocaltrol] ), and thiazide diuretics and dietary modification are typically used as well. PTH therapy has been studied, but data are limited and PTH preparations are not approved by the U.S. Food and Drug Administration for this purpose. *-See screen with measurement of serum calcium levels alone. Others advocate screening with measurement of calcium and PTH levels annually, starting at eight years of age. 19 A discussion with the affected patient and family about screening is warranted. In a family with a history of MEN-2, a sample from one patient already affected should be tested to determine the specific genetic mutation for that family. When a mutation is found, all persons of unknown status in that family should then be definitively genotyped. 10, 21 Rarely, patients with parathyroid disorders may present with a neck mass, either self-reported or as an incidental finding on examination. Parathyroid cancer, hyperplasia, adenomas, and cysts could all present in this way. Other neck tumors, including primary or metastatic cancers, are more common than parathyroid causes. Ultrasonography, computed tomography, and biopsy are typically required to determine the diagnosis. 
